Previous 10 | Next 10 |
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 results Principal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and...
2023-10-31 12:10:22 ET More on Evaxion Biotech ADS Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01 Seeking Alpha ...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Eva...
Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company CO...
2023-10-05 09:40:08 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01 Seeking Alpha’s Quant Rating on Evaxion Biotech ADS Historical earnings...
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a let...
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platform The collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub Afrigen responsible for the development and co...
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms EDEN™ and RAVEN™ will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting bo...
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development Evaxion's AI model predicts vaccine efficacy in infectious disease models These results mean using EDEN TM will allow for a faster, cheaper, and lower-risk vaccine developme...
2023-08-29 09:32:01 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01 Evaxion stock slumps ~10% despite developing AI tool for cancer therapy Evaxio...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...